BioSpace News Archive

Outset Medical, Inc., a medical technology company reducing the cost and complexity of dialysis, announced the appointment of Dale E. Jones to its Board of Directors.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) reached an agreement with BeiGene (Beijing) Co., Ltd. (“BeiGene”) (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully human antibody RenMab™/RenLite™ mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2022.

STERIS plc announced that it will host a conference call to discuss its fiscal 2022 fourth quarter and full year financial results at 10:00 a.m. ET on May 12, 2022.

Dermata Therapeutics, Inc. announced the closing of its previously announced private placement with a single institutional investor of 3,773,585 shares of its common stock and warrants to purchase up to an aggregate of 3,773,585 shares of common stock, for aggregate gross proceeds of $5.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

CoNextions® Inc. (www.conextionsmed.com), an innovator in tendon repair, is pleased to announce that CoNextions TR® Tendon Repair System has received FDA 510(k) Clearance.

Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF (Pulsed Electro-Magnetic Field) product SofPulse®.

Bispecific antibodies are emerging as a novel therapeutic approach, which has potential to treat chronic diseases as well as to diagnose diseases efficiently with fewer side effects.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has received clearance from the FDA for its investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and pharmacokinetics in healthy volunteers.

Conjunctival hyperemia was a key inclusion criterion for the enrollment of patients with ocular surface inflammation and is a recognized clinical sign in patients with ocular surface inflammation and associated dry eye.